Elsevier

Metabolism

Volume 41, Issue 7, July 1992, Pages 683-685
Metabolism

Preliminary report
Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin

https://doi.org/10.1016/0026-0495(92)90303-RGet rights and content

Abstract

The pathway for removal of the circulating potent vasoconstrictor peptide, endothelin (ET), is unclear. To determine the contribution of neutral endopeptidase (NEP) to ET metabolism, urinary excretion (UETV) and plasma levels of ET (PET) were measured after infusion of the NEP inhibitor (NEP-I), SQ 29,072 (30 mg/kg [n = 10] and 60 mg/kg [n = 6]), in anesthetized Munich Wistar rats. Both doses significantly increased UETV at 30, 60, and 90 minutes; the maximal effect was obtained 30 minutes after infusion, and the response was longer in rats pretreated with the higher dose of the inhibitor. PET increased 36% and 55% (P ≤ .05) at 30 and 120 minutes after injection of the larger dose of SQ 29,072. We also studied the effect of NEP-I on the excretion of exogenous ET after the infusion of 125I-ET (1 μCi) in rats pretreated with either NEP-I or vehicle. In rats treated with the lower dose of the inhibitor, urinary radioactivity increased 2.1- and 1.5-fold (P ≤ .05 v control) after 30 and 60 minutes, respectively. After the higher dose of NEP-I, urinary radioactivity increased 2.7- and 1.7-fold (P ≤ .05). The distribution of the urinary radioactivity as defined by high-performance liquid chromatography (HPLC) showed that intact labeled ET accounts for only 6% to 9% of the total counts recovered in urine from control rats, while the remainder was either free iodine or other products of hydrolysis. Intact ET increased significantly in urine from rats pretreated with NEP-I, to 50% to 56% of total radioactivity in urine. These results demonstrate that the inhibition of NEP increases the urinary excretion and plasma levels of ET, and that NEP plays an important role in the metabolism of ET.

References (10)

There are more references available in the full text version of this article.

Cited by (49)

  • Natriuretic peptides and cardio-renal disease

    2014, International Journal of Cardiology
    Citation Excerpt :

    ANP and CNP are the NPs most susceptible to degradation by NEP, whereas the enzyme has a lower affinity for BNP [46]. NEP also degrades other vasoactive peptides including vasodilators, e.g. substance P and bradykinin, and vasoconstrictors such as ET-1 and Ang II [47–51]. Consequently, the net physiological effect of NEP will depend on the balance between its actions on vasodilators versus vasoconstrictors.

  • Effects of Endopeptidase Inhibition on the Contraction-Relaxation Response of Isolated Human Vaginal Tissue

    2013, Journal of Sexual Medicine
    Citation Excerpt :

    The enzyme shares a structural similarity with the so‐called endothelin‐converting enzyme (ECE) and was initially isolated from renal epithelial brush border cells. However, it is also expressed in vascular endothelial and smooth muscle cells [6-10]. In addition to the degradation of vasoactive peptides, NEP also catalyzes the conversion of big endothelin‐1 (Big ET‐1) into ET‐1, a potent vasoconstrictor peptide [11].

  • Inhibition of neointima formation in an organ culture of human saphenous vein: A comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition

    2001, Journal of Vascular Surgery
    Citation Excerpt :

    In conditions characterized by neointima formation, such as arterial bypass grafting, treatment with a dual ECE/NEP inhibitor is likely to compound the clinical problem. Because ET-1 is a substrate for NEP,12 inhibition of NEP will actually raise ET-1 levels. Any studies with dual inhibitors will, by their very nature, be complicated because the observed response could be caused by ECE inhibition, NEP inhibition, or both.

View all citing articles on Scopus

This is a US government work. There are no restrictions on its use.

View full text